Skip to content

阿尔蒂维昂

US · AORT #3212 按市值排名
21.78 -0.09 -0.41%
实时 - 追踪5344个代码 - 心跳于197秒前 · 2026-10-16 19:30

估值 各估值倍数与自身5年区间的对比

市净率 2.36 低于历史水平 第26百分位
5年平均 3.13 · 在Medical Devices中排名第60/125
市盈率 -360.17 低于历史水平 第9百分位
5年平均 -77.66 · 前瞻 274.50
市销率 2.23 低于历史水平 第30百分位
5年平均 2.80 · 前瞻 2.04 · 在Medical Devices中排名第59/136

同业对比 Medical Devices

公司 市值 市盈率(TTM) 市净率 股息率
阿尔蒂维昂 (AORT) 1.06B -363.00 2.38 0.00%
Abbott Laboratories (ABT) 181.50B 33.94 3.55 2.33%
Medtronic (MDT) 121.20B 23.34 2.41 3.01%
Stryker Corp (SYK) 113.02B 30.53 4.71 1.18%
Boston Scientific (BSX) 64.33B 17.97 2.58 0.00%
Edwards Lifesciences (EW) 49.92B 50.35 4.70 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★☆☆ 合理价值34.65 经济护城河None 不确定性High

当前股价低于晨星合理价值估算59.1%。

合理价值

Artivion Inc may seem undervalued at first glance, due to its considerable price decline over the past year. However, to account for the risk associated with a potential value trap, we have limited its rating to 3 stars. The stock currently trades at a 38% discount to our quantitative fair value estimate of $34.65 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The company's balance sheet bolsters our fair value estimate. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. For example, the firm's EBITDA/interest coverage ratio of 2.1 sits in the bottom 20% globally. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. We believe this is a sign that shares could be cheap.

On a different note, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 2.4%, for example, sits in the bottom 45% compared with global peers. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.

经济护城河

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

阿尔蒂维昂 讨论区 0 条评论

发表评论